Sarcoma is a malignant tumour affecting connective tissues, muscular tissues or bones. Those tissues constitute two thirds of the human body and are involved in a number of key functions such as protection, nutrition, liaison, tissue regeneration, movement, immune response, growth or storage. Human sarcomas are rare: around 1% of all new cancer cases, and are found accross all ages. While recent molecular and genetic advances have helped to refine their classification, their diagnosis and therapeutic care still remain a challenge. Conventional chemotherapy as well as targeted therapies failed to provide a long term efficient response. IMS (Integrated medecine for sarcomas), which aims to take part of the recognised expertise of the scientific and medical community of Bordeaux, is a multidisciplinary program that allow experts in genetics, psychology, sociology, epidemiology to work together toward better treatment strategies for sarcomas.


IMS is an ambitious programme dedicated to the enhancement of global outcome of patients with sarcomas through a multidimensional approach integrating:

  • Genomic driven clinical research and massive data integration to improve tumour biology knowledge and to assess impact of new therapies,
  • Pre-clinical investigations to identify new therapeutic targets,
  • Psychological and sociological research to assess impact of sarcoma diagnosis from a patient and society perspective,
  • Epidemiology research to improve environmental exposure assessment as part of a better understanding of the environmental etiology of sarcomas.

IMS coordinators are :

Each dimension of the program dimension are classified in tasks (divided itself in several research programs)  :

The first task « Integration of massive sequencing data to identify molecular networks of sensitivity and resistance to systemic therapies in sarcomas » is led by Dr Carlos Lucchesi, bioinformatician at Institut Bergonié.

In collaboration with H. and C. Fridman from the Laboratoire du microenvironnement immunitaire et des tumeurs, Inserm Paris, the task « Predictive and prognostic value of immunological profiling of soft-tissue sarcoma » is led by Dr Maud Toulmonde, oncologist at Institut Bergonié.

« Metabolic profiling of sensitivity and resistance to targeted therapies in sarcomas and other rare tumours » is led by Dr Rodrigue Rossignol, senior research scientist, team Maladies rares : génétique et métabolisme (MRGM).

« Radiomics Analysis for Characterisation of Prognosis and Treatment Response in Soft Tissue Sarcomas » is led by Dr Amandine Crombe, radiologist at Institut Bergonié.

In collaboration with the SIRIC SOCRATE, the task « make personalised medicine available for sarcoma patients and determination of the methods to communicate about these new practices to the patient » is led by Dr Sylviane darquy, research scientist in the Laboratoire d’éthique médicale et médecine légale, Inserm.

« Development and and assessment of faisability and efficacy of e-MBCR (web-Mindfulness Based Cancer Recovery) program (faisability and efficacy) » is led by Dr Marion Barrault, psychologist at Institut Bergonié and searcher in the Laboratoire de psychologie at University of Bordeaux.

« Emerging environmental factors and sarcomas » is led by Prof. Simone Mathoulin-Pélissier, professor of epidemiology and publich health, head of the team EPICENE, Inserm.

[Page under construction…]